Members of the Chakravarti Lab: Min Zhang, MD, PhD. Postdoctoral Fellow - Massachusetts General Hospital / Harvard Medical School. Email: mzhang5@partners.org Kamalakannan Palanichamy, PhD. Postdoctoral Fellow - Massachusetts General Hospital / Harvard Medical School. Email: kpalanichamy@partners.org Tim Lautenschlaeger, MD. Postdoctoral Fellow - Massachusetts General Hospital / Harvard Medical School. Email: TLautenschlaeger@partners.org Shinei Noda, MD, PhD. Postdoctoral Fellow - Massachusetts General Hospital/Harvard Medical School. Email: SNoda@partners.org Michael Siedow, BS. Labmanager / Research Assistant. Massachusetts General Hospital / Harvard Medical School. Email: MSiedow@partners.org Disha Patel, BS Labmanager / Research Assistant. Massachusetts General Hospital / Harvard Medical School. Email: DPatel7@partners.org Students: Vincent Depalo Jenna Kahn Angelika Modelska Anshu Shukla Zachary Reardon Nikol Mladkova Mike Erkkinen (alumni) Greg Saia (alumni) Erin Tyndall (alumni)

Molecular and Cellular Radiation Neuro-Oncology Laboratory

The Chakravarti Lab: The Laboratory of Molecular and Cellular Radiation Neuro-Oncology

Research Interests: To investigate the underlying mechanisms of therapeutic resistance, focusing on tumors of the central nervous system and GU cancers.

Richard B. Simches Research Center,
Brain Tumor Research Center,
Massachusetts General Hospital
CPZN-3-3800
617-643-3427 (phone)
617-643-3229 (fax)
achakravarti@partners.org

Selected Publications [MCRNOL Publications & PubMed Links]:

Chakravarti, A. ; Loeffler, J. S. ; Dyson, N..J. Insulin-like growth factor receptor I (IGFRI) mediates resistance to anti-epidermal growth factor receptor (EGFR) therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002; 62(1):200-207.

Chakravarti, A.; Noll, E.; Black, P.B.; Dyson, N.J.; Loeffler, J.S. Quantitatively-determined Survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002; 20(4):1063-1068

Chakravarti, A.; Chakladar, A.; Delaney, M.A.; Latham, D.E.; Loeffler, J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002; 62(15):4307-4315

Chakravarti, A.; Heydon, K.; Wu, C-L; Hammond, E.; Pollack, A.; Roach, M.; Wolkov, H.; Okunieff, P; Komaki, R.; Fontanesi, J; Abrams, R.; Pilepich, M.; Shipley, W. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from RTOG 86-10. J Clin Oncol 2003;

Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P.; Muzikansky, A. ; Loeffler, J. The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas. J Clin Oncol 2004 May 15;22(10):1926-33.

Zhang, M., Chakravarti, A. Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol. 2006 Jan;16(1):29-37.

Chakravarti, A.; Zhang, M.; Khor, L-Y.; Pollack, A.; Shipley, W. The prognostic value of p16 in locally-advanced prostate cancer: a report from RTOG 9202. J. Clin Oncol 2007; 25(21): 3082-3089.

Stupp, R., Hegi, M.; Gilbert, M.; Chakravarti, A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin Oncol 2007; 25(26): 4127-4136.